Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G 1 Fragments
The DOI matches its Crossref record.
Abstract
Preparation of bispecific antibodies by the chemical reassociation of monovalent fragments derived from monoclonal mouse immunoglobulin G1 is inefficient because of side reactions during reoxidation of the multiple disulfide bonds linking the heavy chains. These side reactions can be avoided by using specific dithiol complexing agents such as arsenite and effecting disulfide formation with a thiol activating agent such as 5,5′-dithiobis(2-nitrobenzoic acid). In this way bispecific antibodies were obtained in high yield and free of monospecific contaminants from monoclonal mouse immunoglobulin G1 fragments. The bispecific antibodies were used as agents for the selective immobilization of enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
“More efficient production of BsF(ab′)2 fragments was achieved using cysteine-reactive homo- and heterobifunctional crosslinking reagents (Brennan et al., 1985; Glennie ar formats and therapeutic applications for bispecific antibodies.”
MethodAntibody‐Conjugated Nanoparticles for Biomedical Applications
Arruebo, M., Valladares, M., & González-Fernández, Á. (2009) · Journal of Nanomaterials · doi:10.1155/2009/439389 · Cited by 331
High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment
Carter, P., Kelley, R. F., Rodrigues, M. L., Snedecor, B., Covarrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., et al. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-163 · Cited by 330
New protein engineering approaches to multivalent and bispecific antibody fragments
Plückthun, A., & Pack, P. (1997) · Immunotechnology · doi:10.1016/s1380-2933(97)00067-5 · Cited by 322
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Z., Liu, M., Zhang, Y., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01084-4 · Cited by 282
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
A revival of bispecific antibodies
Kufer, P., Lutterbüse, R., & Baeuerle, P. A. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.006 · Cited by 157
“Other approaches used chemical conjugation of two different monoclonal antibodies or smaller antibody fragments [ 18 ].”
MethodDevelopments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
“Other explored approaches include: (1) chemical conjugation of two different monoclonal antibodies or smaller antibody fragments [244], (2) ‘Knobs-into-holes’ strategy [245,246], and (3) strand-exchange engineered domain (SEED) [247].”
Background
Metadata
- Authors
- Brennan, M., Davison, P. F., & Paulus, H.
- Venue
- Science
- Published
- 1985-07-05
- Volume
- 229
- Issue
- 4708
- Pages
- 81-83
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2050557902
- Cited by
- 251
- References
- 0
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.